KACTUS is a biotech company focused on advancing cell and gene therapy through high-purity, high-activity recombinant proteins and enzymes. Our portfolio supports key areas such as immunotherapy, gene editing, mRNA therapeutics, and antibody drug discovery. With a catalog of over 3,000 ready-made recombinant proteins—covering diverse targets, species, tags, and labels—we are committed to quality and innovation. Each product is selected to address unmet research needs and accelerate scientific breakthroughs. By offering first-to-market reagents tailored to emerging therapeutic areas, KACTUS empowers researchers to drive the next generation of biopharma and diagnostic development.